Nanotechnology and glaucoma: A review of the potential implications of glaucoma nanomedicine

British Journal of Ophthalmology

Volumn 98, Issue 4, 2014, Pages 427-431

  Kim, Nathaniel J ^a   Harris, Alon ^a   Gerber, Austin ^a   Tobe, Leslie Abrams ^a   Amireskandari, Annahita ^a   Huck, Andrew ^a   Siesky, Brent ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O LAURYL LEVO ASCORBIC ACID; ACETAZOLAMIDE; ANTIGLAUCOMA AGENT; BRIMONIDINE; BRINZOLAMIDE; CARBOMER; CARTEOLOL; DENDRIMER; DRUG CARRIER; EUDRAGIT; GLUCOSAMINE; GLYCERYLTRIACRYLATE NANOPARTICLE; HYDROXYLETHYLMETHACRYLATE; IOBRIM; LATANOPROST; LIPOSOME; MACROGOL; MITOMYCIN; NANOMATERIAL; NANOPARTICLE; PHOSPHATIDYLCHOLINE; PILOCARPINE; POLYAMIDOAMINE; POLYGLACTIN; POLYMER; QUANTUM DOT; SMALL INTERFERING RNA; TIMOLOL; TIMOLOL MALEATE; TROPICAMIDE; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT;

AQUEOUS HUMOR FLOW; ARTIFICIAL NANODRAINAGE IMPLANT; BIOSENSOR; BLEACHING; BLEB LEAK; CARBOXY TERMINAL SEQUENCE; CONTACT LENS; CORNEA THICKNESS; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; DRUG TARGETING; DRUG TISSUE LEVEL; ENDOPHTHALMITIS; FLUORESCENCE IMAGING; GLAUCOMA; GLAUCOMA DRAINAGE IMPLANT; GLAUCOMA SURGERY; GOLDMANN APPLANATION TONOMETER; HUMAN; HYDROGEL; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE MEASURING DEVICE; IRIDOTOMY; LASER SURGERY; LYMPHATIC DRAINAGE; NANODEVICE; NANOFABRICATION; NANOMEDICINE; NANOTECHNOLOGY; NERVE FIBER REGENERATION; NONHUMAN; OPTIC NERVE INJURY; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SCAR; SUBCONJUNCTIVAL SCAR; TRABECULAR MESHWORK; TRABECULECTOMY; PROCEDURES;

ANTIHYPERTENSIVE AGENTS; DRUG DELIVERY SYSTEMS; GLAUCOMA; HUMANS; LIPOSOMES; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY;

EID: 84896542786     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-304028     Document Type: Review

References (53)

1. United States National Nanotechnology Initiative. What it is and how it works. National Nanotechnology Institute. http://www.nano.gov/nanotech-101/what (accessed 10 Aug 2012).
2. Li X, Chen H, Dang Y, et al. A longitudinal analysis of nanotechnology literature: 1976-2004. J Nanopart Res 2008;10(S1):3-22.
3. Wagner V, Dullaart A, Bock AK, et al. The emerging nanomedicine landscape. Nat Biotechnol 2006;24:1211-17.
4. Zarbin MA, Montemagno C, Leary JF, et al. Nanotechnology in ophthalmology. Can J Ophthalmol 2010;45:457-76.
5. Zarbin MA, Montemagno C, Leary JF, et al. Nanomedicine in ophthalmology: the new frontier. Am J Ophthalmol 2010;150:144-62.e2.
6. United States National Nanotechnology Initiative. What?s so special about the nanoscale? National Nanotechnology Institute. http://www.nano.gov/nanotech- 101/ special (10 Aug 2012).
7. Leske MC. Open-Angle glaucoma-An epidemiologic overview. Ophthalmic Epidemiol 2007;14:166-72.
8. Cholkar K, Patel SP, Vadlapudi AD, et al. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther 2013;29:106-23.
9. Macha S, Mitra AK, Hughes PM. Overview of ocular drug delivery. In: Mitra AK, ed. Ophthalmic drug delivery systems. New York, NY: Marcel Dekker, Inc., 2003:1-12.
10. Stone JL, Robin AL, Novack GD, et al. An objective evaluation of eyedrop instillation in patients with glaucoma. Arch Ophthalmol 2009;127:732-6.
11. Gupta R, Patil B, Shah BM, et al. Evaluating eye drop instillation technique in glaucoma patients. J Glaucoma 2012;21:189-92.
12. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1:297-315.
13. Mastrobattista E, Koning GA, Van Bloois L, et al. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem 2002;277:27135-43.
14. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2005;2:99-107.
15. Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 2009;26:523-80.
16. Natarajan JV, Ang M, Darwitan A, et al. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Int J Nanomedicine 2012;7:123-31.
17. Bhagav P, Upadhyay H, Chandran S. Brimonidine tartrate-eudragit long-Acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. AAPS PharmSciTech 2011;12:1087-101.
18. Yang H, Tyagi P, Kadam RS, et al. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano 2012;6: 7595-606.
19. Yang H, Leffler CT. Hybrid dendrimer hydrogel/poly(lactic-co-glycolic acid) nanoparticle platform: an advanced vehicle for topical delivery of antiglaucoma drugs and a likely solution to improving compliance and adherence in glaucoma management. J Ocul Pharmacol Ther 2013;29:166-72.
20. Tártara LI, Quinteros DA, Saino V, et al. Improvement of acetazolamide ocular permeation using ascorbyl laurate nanostructures as drug delivery system. J Ocul Pharmacol Ther 2012;28:102-9.
21. Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 2005;102:23-38.
22. Holden CA, Tyagi P, Thakur A, et al. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine 2012;8:776-83.
23. Spataro G, Malecaze F, Turrin CO, et al. Designing dendrimers for ocular drug delivery. Eur J Med Chem 2010;45:326-34.
24. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small 2008;4: 26-49.
25. Kambhampati SP, Kannan RM. Dendrimer nanoparticles for ocular drug delivery. J Ocul Pharmacol Ther 2013;29:151-65.
26. Del Pozo-Rodr?guez A, Delgado D, Gascón AR, et al. Lipid nanoparticles as drug/ gene delivery systems to the retina. J Ocul Pharmacol Ther 2013;29:173-88.
27. Lee GA, Khaw PT, Ficker LA, et al. The corneal thickness and intraocular pressure story: where are we now? Clin Experiment Ophthalmol 2002;30:334-7.
28. Graham SL, Drance SM. Nocturnal hypotension: role in glaucoma progression. Surv Ophthalmol 1999;43(Suppl 1):S10-16.
29. Leonardi M, Pitchon EM, Bertsch A, et al. Wireless contact lens sensor for intraocular pressure monitoring: assessment on enucleated pig eyes. Acta Ophthalmol 2009;87:433-7.
30. Faschinger C, Mossböck G. Continuous 24 h monitoring of changes in intraocular pressure with the wireless contact lens sensor Triggerfish?. First results in patients. Ophthalmologe 2010;107:918-22.
31. Rizq RN, Choi WH, Eilers D, et al. Intraocular pressure measurement at the choroid surface: a feasibility study with implications for implantable microsystems. Br J Ophthalmol 2001;85:868-71.
32. Dresher RP, Irazoqui PP. A compact nanopower low output impedance CMOS operational amplifier for wireless intraocular pressure recordings. Conf Proc IEEE Eng Med Biol Soc 2007;2007:6056-9.
33. Chen P-J, Rodger DC, Saati S, et al. Microfabricated implantable parylene-based wireless passive intraocular pressure sensors. J Microelectromech Syst 2008;17: 1342-51.
34. Chen P-J, Rodger DC, Humayan MS, et al. Unpowered spiral-tube parylene-based pressure sensors for intraocular pressure sensing. Sensors and Actuators A: Physical 2006;127:276-82.
35. Chen P-J, Rodger DC, Agrawal R, et al. Implantable micro-mechanical parylenebased pressure sensors for unpowered intraocular pressure sensing. J Micromech Microeng 2007;17:1931-8.
36. Tam AL, Gupta N, Zhang Z, et al. Quantum dots trace lymphatic drainage from the mouse eye. Nanotechnology 2011;22:425101.
37. Pan T, Brown JD, Ziaie B. An artificial nano-drainage implant (ANDI) for glaucoma treatment. Conf Proc IEEE Eng Med Biol Soc 2006;1:3174-7.
38. Maleki T, Chitnis G, Park JH, et al. Biodegradable microfabricated plug-filters for glaucoma drainage devices. IEEE Trans Biomed Eng 2012;59:1507-13.
39. Jung HJ, Chauhan A. Extended release of timolol from nanoparticle-loaded fornix insert for glaucoma therapy. J Ocul Pharmacol Ther 2013;29:229-35.
40. Nanni C. Complications of laser surgery. Dermatol Clin 1997;15:521-34.
41. Konig K, Krauss O, Riemann I. Intratissue surgery with 80 MHz nanojoule femtosecond laser pulses in the near infrared. Opt Express 2002;10:171-6.
42. Fan CH, Sun J, Longtin JP. Breakdown threshold and localized electron density in water induced by ultrashort laser pulses. J Appl Phys 2002;91:2530-6.
43. Serbin J, Bauer T, Fallnich C, et al. Femtosecond lasers as a novel tool in dental surgery. Appl Surface Sci 2002;8101:1-4.
44. Ngoi BK, Hou DX, Koh LH, et al. Femtosecond laser for glaucoma treatment: a study on ablation energy in pig iris. Lasers Med Sci 2005;19:218-22.
45. Parrish R, Minckler D. "Late endophthalmitis"-filtering surgery time bomb? Ophthalmology 1996;103:1167-8.
46. Greenfield DS, Su?er IJ, Miller MP, et al. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol 1996;114:943-9.
47. Greenfield DS, Liebmann JM, Jee J, et al. Late-onset bleb leaks after glaucoma filtering surgery. Arch Ophthalmol 1998;116:443-7.
48. Shaunak S, Thomas S, Gianasi E, et al. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 2004;22:977-84.
49. Ye H, Qian Y, Lin M, et al. Cationic nano-copolymers mediated IKK? Targeting siRNA to modulate wound healing in a monkey model of glaucoma filtration surgery. Mol Vis 2010;16:2502-10.
50. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
51. Uwe S. Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochem Pharmacol 2008;75:1567-79.
52. Zarbin MA, Montemagno C, Leary JF, et al. Nanomedicine for the treatment of retinal and optic nerve diseases. Curr Opin Pharmacol 2013;13:134-48.
53. De Lima S, Koriyama Y, Kurimoto T, et al. Full-length axon regeneration in the adult mouse optic nerve and partial recovery of simple visual behaviors. Proc Natl Acad Sci USA 2012;109:9149-54.